BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 28801607)

  • 1. Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.
    Yang L; Shen M; Xu LJ; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO
    Sci Rep; 2017 Aug; 7(1):7958. PubMed ID: 28801607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FASN-TGF-β1-PD-L1 axis contributes to the development of resistance to NK cell cytotoxicity of cisplatin-resistant lung cancer cells.
    Shen M; Tsai Y; Zhu R; Keng PC; Chen Y; Chen Y; Lee SO
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Mar; 1863(3):313-322. PubMed ID: 29306075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway.
    Shen M; Xu Z; Xu W; Jiang K; Zhang F; Ding Q; Xu Z; Chen Y
    J Exp Clin Cancer Res; 2019 Apr; 38(1):149. PubMed ID: 30961670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway.
    Shen MJ; Xu LJ; Yang L; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
    Oncotarget; 2017 Oct; 8(46):80506-80520. PubMed ID: 29113321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer.
    Zhang F; Shen M; Yang L; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
    Cancer Biol Ther; 2017 Aug; 18(8):606-615. PubMed ID: 28686074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
    Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
    Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
    Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A FASN-TGF-β1-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant non-small cell lung cancer.
    Yang L; Zhang F; Wang X; Tsai Y; Chuang KH; Keng PC; Lee SO; Chen Y
    Oncotarget; 2016 Aug; 7(34):55543-55554. PubMed ID: 27765901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
    Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune.
    Jiang Z; Yang Y; Yang Y; Zhang Y; Yue Z; Pan Z; Ren X
    Biomed Pharmacother; 2017 Dec; 96():378-383. PubMed ID: 29031195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased infiltration of macrophages to radioresistant lung cancer cells contributes to the development of the additional resistance of tumor cells to the cytotoxic effects of NK cells.
    Shen M; Chen Y; Xu L; Zhu R; Xue X; Tsai Y; Keng PC; Lee SO; Chen Y
    Int J Oncol; 2018 Jul; 53(1):317-328. PubMed ID: 29750425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
    Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
    Oncol Rep; 2019 Aug; 42(2):839-848. PubMed ID: 31173242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro-induced M2 type macrophages induces the resistance of prostate cancer cells to cytotoxic action of NK cells.
    Xu L; Shen M; Chen X; Yang DR; Tsai Y; Keng PC; Lee SO; Chen Y
    Exp Cell Res; 2018 Mar; 364(1):113-123. PubMed ID: 29408565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer.
    Hu W; Ma Y; Zhao C; Yin S; Hu H
    Mol Carcinog; 2021 Nov; 60(11):746-757. PubMed ID: 34411338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer.
    Wang F; Wu L; Yin L; Shi H; Gu Y; Xing N
    Clin Transl Med; 2022 Jun; 12(6):e901. PubMed ID: 35696531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
    Kim SJ; Kim S; Kim DW; Kim M; Keam B; Kim TM; Lee Y; Koh J; Jeon YK; Heo DS
    Cancer Res Treat; 2019 Jul; 51(3):1231-1240. PubMed ID: 30653748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer.
    Fournel L; Wu Z; Stadler N; Damotte D; Lococo F; Boulle G; Ségal-Bendirdjian E; Bobbio A; Icard P; Trédaniel J; Alifano M; Forgez P
    Cancer Lett; 2019 Nov; 464():5-14. PubMed ID: 31404614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
    Suda K; Rozeboom L; Rivard CJ; Yu H; Ellison K; Melnick MAC; Hinz TK; Chan D; Heasley LE; Politi K; Mitsudomi T; Hirsch FR
    Lung Cancer; 2017 Jul; 109():1-8. PubMed ID: 28577937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
    Wang N; Song L; Xu Y; Zhang L; Wu Y; Guo J; Ji W; Li L; Zhao J; Zhang X; Zhan L
    EBioMedicine; 2019 Sep; 47():65-77. PubMed ID: 31495720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells.
    Yan F; Pang J; Peng Y; Molina JR; Yang P; Liu S
    PLoS One; 2016; 11(9):e0162925. PubMed ID: 27610620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.